Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Rinesmith

Internal Medicine Lima, OH Medical Doctor

NPI 1790837433 CMS profile 36573

2793 Shawnee Rd, Lima, OH 45806

Open in the dashboard

General payments

$12,947

777 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$51,285 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Scott Rinesmith of Lima, OH is reported in the CMS Open Payments database as having received $12,947 across 777 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $51,285 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,454 128
2024 General $2,982 158
2023 General $2,334 135
2022 General $1,816 114
2021 General $1,362 94
2020 General $585 49
2019 General $1,415 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Rinesmith
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Scott Rinesmith were reported at $2,454. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Scott Rinesmith Internal Medicine median Middle half National median
2019 $1,415 $159 $48–$570 $163
2020 $585 $119 $33–$402 $114
2021 $1,362 $135 $37–$521 $132
2022 $1,816 $141 $42–$496 $149
2023 $2,334 $149 $45–$519 $160
2024 $2,982 $154 $47–$537 $164
2025 $2,454 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,165 235 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $2,062 113 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,762 127 payments
  4. Janssen Biotech, Inc. $808 35 payments
  5. Gilead Sciences, Inc. $475 24 payments
  6. QOL Medical, LLC $445 22 payments
  7. Pfizer Inc. $368 18 payments
  8. Ardelyx, Inc. $294 15 payments
  9. Intercept Pharmaceuticals, Inc. $283 8 payments
  10. Merck Sharp & Dohme Corporation $276 19 payments
  11. Other $3,009 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,679 771 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  3. Education $118 5 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,321 96 payments
  2. ENTYVIO $1,037 63 payments
  3. RINVOQ $1,020 69 payments
  4. CREON $700 55 payments
  5. LINZESS $698 53 payments
  6. STELARA $670 27 payments
  7. MAVYRET $560 44 payments
  8. HUMIRA $501 43 payments
  9. TRULANCE $405 28 payments
  10. XELJANZ $343 17 payments
  11. Other $7,481 412 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

1,054

Median for Gastroenterology: 569

Drug cost

$88,179

Median for Gastroenterology: $104,976

Branded share of claims

16.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 12 $42,579
Mesalamine Generic 28 $10,394
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 125 $8,050
Linzess Linaclotide Brand 12 $6,837
Colestipol Hcl Generic 35 $4,525
Sucralfate Generic 235 $4,257
Pantoprazole Sodium Generic 186 $2,290
Lansoprazole Generic 14 $2,263
Omeprazole Generic 236 $2,030
Esomeprazole Magnesium Generic 18 $1,238

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$211,249

Medicare's payments for the services billed

Medicare patients

462

Average age 73

Services billed

8,117

233 women, 229 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 50%
Ischemic heart disease 37%
Diabetes 34%
Heart failure 23%
Chronic kidney disease 23%
Atrial fibrillation 22%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $359
$359 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $331
$331 12 —
RINVOQ
  • AbbVie, Inc. $178
$178 — —
STELARA
  • Janssen Biotech, Inc. $156
$156 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

777 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record